Diagnostic Products Corporation Schedules Conference Call to Discuss Second Quarter 2005 Results
July 12 2005 - 8:01AM
Business Wire
Diagnostic Products Corporation (NYSE:DP) announced today that it
has scheduled a conference call to discuss the Company's financial
results of its second quarter 2005 on Monday, July 25, 2005, at 9
a.m. Eastern standard time (6 a.m. PST). The Company plans to
release its financial results before the market opens on Friday. If
you are interested in participating in the call, please call
800-260-6066 on the day of the conference, at least ten minutes
prior to the conference in order for the operator to tie you into
the call. The operator will ask you to identify the call with the
company name Diagnostic Products-Jim Brill. An "instant replay" of
the call will be available until August 4. If you would like to
take advantage of this special service, you can access it via
800-839-6713 and the code: "7241305." It usually takes two hours
following the conference to set up the recording. About Diagnostic
Products Corporation Diagnostic Products Corporation, founded in
1971, is the global leader dedicated exclusively to
immunodiagnostics. DPC's product menu includes over 75 immunoassays
and more than 365 specific allergens and allergy panels. In
addition, DPC addresses the chemistry and laboratory automation
testing needs of its customers through partnerships with
manufacturers of chemistry systems and reagents. The combined
chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested.
DPC also designs and manufactures automated laboratory
instrumentation, which provides fast, accurate results while
reducing labor and reagent costs. DPC sells its products to
hospitals, clinics and laboratories in more than 100 countries.
*Additional Company information can be found on DPC's website at
www.dpcweb.com. Except for the historical information contained
herein, this press release contains forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially. These factors include the effects of
governmental or other actions relating to the FDA's decision that
its Application Integrity Policy should be applied to the Company
or relating to the Company's Chinese affiliate; the rate of
customer demand for the Company's products; the Company's ability
to successfully market new and existing products; its dependence on
certain suppliers; domestic and foreign government regulation; its
ability to keep abreast of technological innovations and to
translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC
reports and filings.
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From May 2024 to Jun 2024
Diagnostic Products (NYSE:DP)
Historical Stock Chart
From Jun 2023 to Jun 2024